Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade A 62.39 3.33% 2.01
CCXI closed up 3.33 percent on Friday, May 29, 2020, on 1.11 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical CCXI trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week High Strength 3.33%
Upper Bollinger Band Walk Strength 3.33%
Multiple of Ten Bullish Other 3.33%
Overbought Stochastic Strength 3.33%
Upper Bollinger Band Touch Strength 3.33%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Medicine Biopharmaceutical Cancer Immunology Autoimmune Diseases Monoclonal Antibodies Rheumatoid Arthritis Inflammatory Bowel Disease Atopic Dermatitis Diabetic Nephropathy Dermatitis Immunosuppressants Kidney Disease Biotie Therapies Glioblastoma Multiforme Inflammatory Disorders Janus Kinase Inhibitor Inflammatory Disease

Is CCXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 63.7769
52 Week Low 6.16
Average Volume 595,465
200-Day Moving Average 30.53
50-Day Moving Average 49.30
20-Day Moving Average 56.55
10-Day Moving Average 59.26
Average True Range 3.64
ADX 28.62
+DI 23.99
-DI 14.44
Chandelier Exit (Long, 3 ATRs ) 52.85
Chandelier Exit (Short, 3 ATRs ) 60.19
Upper Bollinger Band 63.49
Lower Bollinger Band 49.61
Percent B (%b) 0.92
BandWidth 24.54
MACD Line 3.29
MACD Signal Line 2.97
MACD Histogram 0.3143
Fundamentals Value
Market Cap 3.04 Billion
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -100.63
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 69.28
Resistance 3 (R3) 68.60 65.62 68.13
Resistance 2 (R2) 65.62 63.87 65.96 67.74
Resistance 1 (R1) 64.01 62.79 64.82 64.69 67.36
Pivot Point 61.03 61.03 61.44 61.37 61.03
Support 1 (S1) 59.42 59.28 60.23 60.10 57.42
Support 2 (S2) 56.44 58.20 56.78 57.04
Support 3 (S3) 54.83 56.44 56.65
Support 4 (S4) 55.51